$2,391.05 general Payment -- Novartis Pharmaceuticals to Dr. Andrew Young
Novartis Pharmaceuticals pays Ophthalmologist Andrew Young $2,391.05 for services related to Rinvoq
This page provides a detailed analysis of a $2,391.05 general payment from Novartis Pharmaceuticals to Dr. Andrew Young. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $2,391.05 |
| Payment Type | general |
| Payment Nature | Compensation for services other than consulting |
| Pharmaceutical Company | Novartis Pharmaceuticals |
| Physician | Dr. Andrew Young |
| NPI Number | 1850826606 |
| Physician Specialty | Ophthalmology |
| Location | Miami, FL |
| Date of Payment | 2025-02-05 |
| Related Drug/Device | Rinvoq |
| Conflict Assessment | Moderate -- Worth Noting |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Novartis Pharmaceuticals made a $2.4K general payment to Andrew Young, a Ophthalmology specialist in Miami, FL. The payment was associated with Rinvoq. The payment of $2,391.05 to Dr. Andrew Young in Miami, FL, is for services related to Novartis Pharmaceuticals' drug Rinvoq. This payment falls under the 'general' payment type and is categorized as compensation for services other than consulting. The payment was made on February 5, 2025, and is associated with payment ID OP-MNGJCH7G-5Q2290.
Patient Guidance: What This Payment Means for You
This payment to your physician is for services rendered and may be related to the use or discussion of specific medications or devices. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
Payments to ophthalmologists for services other than consulting can vary widely depending on the nature of the service, but this amount is moderate for a single service payment.
Regulatory Context: Sunshine Act Requirements
This transaction is reported under the Physician Payments Sunshine Act, a provision of the Affordable Care Act, requiring disclosure of payments made by manufacturers to physicians and teaching hospitals.
Related Topics
This payment is related to the following healthcare transparency topics:
- pharmaceutical-payments
- physician-compensation
- ophthalmology
- drug-rinvoq
- novartis-pharmaceuticals
- cms-open-payments
Understanding general Payments
general payments are one of several categories of financial transfers from pharmaceutical and medical device companies to physicians that must be reported under the Sunshine Act. Understanding the type and context of a payment is important for evaluating its significance. Not all payments are equal -- a research grant has very different implications than a promotional speaking fee.
Frequently Asked Questions About This Payment
What was this $2.4K payment for?
This was a general payment of $2.4K from Novartis Pharmaceuticals to Andrew Young, categorized as "Compensation for services other than consulting". It was associated with Rinvoq. The payment was reported under the Sunshine Act (CMS Open Payments).
Does Andrew Young accept pharmaceutical money?
Yes, Andrew Young received this $2.4K payment from Novartis Pharmaceuticals. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Andrew Young's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this general payment?
A general payment of $2.4K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Ophthalmology?
To compare this payment against Ophthalmology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Ophthalmology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Andrew Young's relationship with Novartis Pharmaceuticals?
The payment amount is specific and itemized. This $2.4K general payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Ophthalmology?
The payment is for 'services other than consulting,' indicating a direct service provided by the physician.
What should patients do after learning about this payment?
This payment to your physician is for services rendered and may be related to the use or discussion of specific medications or devices.
What else should I know about this general payment?
The drug associated with the payment, Rinvoq, is a significant product for Novartis.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.